Your browser doesn't support javascript.
loading
Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy.
Ortolan, E; Appierto, V; Silvestri, M; Miceli, R; Veneroni, S; Folli, S; Pruneri, G; Vingiani, A; Belfiore, A; Cappelletti, V; Vismara, M; Dell'Angelo, F; De Cecco, L; Bianchi, G V; de Braud, F G; Daidone, M G; Di Cosimo, S.
Afiliação
  • Ortolan E; Biomarkers Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Appierto V; Biomarkers Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Silvestri M; Biomarkers Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Miceli R; Clinical Epidemiology and Trial Organization Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Veneroni S; Biomarkers Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Folli S; Breast Cancer Unit, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Pruneri G; Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Vingiani A; Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Belfiore A; Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Cappelletti V; Biomarkers Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Vismara M; Biomarkers Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Dell'Angelo F; Biomarkers Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • De Cecco L; Integrated Biology Platform, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Bianchi GV; Department of Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • de Braud FG; Department of Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Daidone MG; Biomarkers Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address: mariagrazia.daidone@istitutotumori.mi.it.
  • Di Cosimo S; Biomarkers Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
ESMO Open ; 6(2): 100086, 2021 04.
Article em En | MEDLINE | ID: mdl-33743331
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias de Mama Triplo Negativas / DNA Tumoral Circulante Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: ESMO Open Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Itália
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias de Mama Triplo Negativas / DNA Tumoral Circulante Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: ESMO Open Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Itália